BioForce Nanosciences Holdings, Inc. develops and commercializes nanotech tools and solutions for the life sciences. BioForce's flagship product, the Nano eNabler molecular printer, gives the Company a platform for development and discovery. BioForce technology is being used in sensor functionalization; patterning and cell adhesion; and printing proteins to guide neural cell growth.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-0.49M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -30513.47% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.05 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.05 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.01 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.04 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 33.52M |
| Free Float | 20.27M |
| Market Capitalization | $16.88M |
| Average Volume (Last 20 Days) | 558.50 |
| Beta (Past 60 Months) | -0.93 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 39.54% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |